Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Plasma cell leukemia: advantages of treatment with bortezomib

Plasma cell leukemia: advantages of treatment with bortezomib Plasma cell leukemia is an aggressive variant of multiple myeloma affecting 4% of all cases of the latter. It is characterized by the presence of at least 20% plasma cells circulating in the peripheral blood, equivalent to an absolute number greater than 2,000/mm3. Plasma cell leukemia exits in two forms: primary or de novo plasma cell leukemia (60%) and the secondary form, which consists of a leukemia transformation of a multiple myeloma (40% plasma cell leukemia and 1% multiple myeloma). The disease is rare and has poor prognosis, as there is no effective therapy except the standard melphalan–prednisone combination. We report here on a case of primary plasma cell leukemia diagnosed in the Nice University Hospital’s Onco-hematology Department, which achieved complete response (CR) after eight cycles of bortezomib-cexamethasone followed by maintenance treatment with bortezomib. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Targeted Oncology Springer Journals

Plasma cell leukemia: advantages of treatment with bortezomib

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/plasma-cell-leukemia-advantages-of-treatment-with-bortezomib-XWplc01DKo

References (16)

Publisher
Springer Journals
Copyright
Copyright © 2008 by Springer-Verlag
Subject
Medicine & Public Health; Biomedicine general; Oncology
ISSN
1776-2596
eISSN
1776-260X
DOI
10.1007/s11523-008-0096-3
Publisher site
See Article on Publisher Site

Abstract

Plasma cell leukemia is an aggressive variant of multiple myeloma affecting 4% of all cases of the latter. It is characterized by the presence of at least 20% plasma cells circulating in the peripheral blood, equivalent to an absolute number greater than 2,000/mm3. Plasma cell leukemia exits in two forms: primary or de novo plasma cell leukemia (60%) and the secondary form, which consists of a leukemia transformation of a multiple myeloma (40% plasma cell leukemia and 1% multiple myeloma). The disease is rare and has poor prognosis, as there is no effective therapy except the standard melphalan–prednisone combination. We report here on a case of primary plasma cell leukemia diagnosed in the Nice University Hospital’s Onco-hematology Department, which achieved complete response (CR) after eight cycles of bortezomib-cexamethasone followed by maintenance treatment with bortezomib.

Journal

Targeted Oncology – Springer Journals

Published: Nov 20, 2008

There are no references for this article.